Basic Information
| RNALocate ID: | RLID:11002554 |
| RNA Symbol: | hsa-miR-382-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-382 |
| RNA ID: | miRBase:MIMAT0000737 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 20615901 |
| Tissue/Cell Line: | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) |
| Method: | Microarray|RT-PCR |
|
Originally published in Nucleic Acids Res. Wang K, et al, 2010. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
| Description: | These observations of miRNA distribution demonstrate that the miRNA export system in the cells must somehow be able to target specific miRNAs to specific extracellular structures, but does not exclusively channel specific miRNAs to a given fraction. There are, however, some miRNAs that are found in the supernatant almost to the exclusion of all other fractions (miR-219 in A549 culture medium, Figure 4b, for example). Another significant observation from this data is that even though we showed that the two cell lines studied here export a similar spectrum of miRNAs (Figure 1b) the distributions of miRNAs from the two cell lines demonstrate clear differences, as shown in Figure 4b and c. For example, miR-145 is present at very low levels in HepG2 derived microvesicles (Figure 4c), while the same miRNA is present at significant levels in both A549 derived microvesicles and exosomes (Figure 4b). On the other hand, there are some miRNAs, notably those that are almost uniformly distributed among the fractions, with the same distribution no matter which cell-line is the source. These observations certainly indicate the degree of complexity of this export system that will bear further investigation. Data are collected from Figure 4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002047 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:11002548 | Exosome | Serum | 18589210 |
| RLID:11002549 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11002550 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11002551 | Exosome | Brain tissue | 23382797 |
| RLID:11002552 | Exosome | Plasma | 23663360 |
| RLID:11002553 | Exosome | B cell lymphoma cell lines|EBV-transformed lymphoblastoid B cells | 25242326 |
| RLID:11002555 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000126 | Exosome | Blood | |
| RLID-D:11000425 | Microvesicle | Blood|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-382-5p | Pheochromocytoma | MNDR-E-MI-47191 |
| MNDR | hsa-miR-382-5p | Oral squamous cell carcinoma | MNDR-E-MI-47192 |
| MNDR | hsa-miR-382-5p | Medulloblastoma | MNDR-E-MI-47193 |
| MNDR | hsa-miR-382-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-47194 |
| MNDR | hsa-miR-382-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-47195 |
| MNDR | hsa-miR-382-5p | Lymphoma | MNDR-E-MI-47196 |
| MNDR | hsa-miR-382-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-47197 |
| MNDR | hsa-miR-382-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-47198 |
| MNDR | hsa-miR-382-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-47199 |
| MNDR | hsa-miR-382-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-47200 |
| MNDR | hsa-miR-382-5p | Her2-receptor positive breast cancer | MNDR-E-MI-47201 |
| MNDR | hsa-miR-382-5p | Niemann-pick disease type c | MNDR-E-MI-47202 |
| MNDR | hsa-miR-382-5p | Dermatomyositis | MNDR-E-MI-47203 |
| MNDR | hsa-miR-382-5p | Gastric cancer | MNDR-E-MI-47204 |
| MNDR | hsa-miR-382-5p | Alzheimer disease | MNDR-E-MI-47205 |
| MNDR | hsa-miR-382-5p | Dysautonomia familial | MNDR-E-MI-47206 |
| MNDR | hsa-miR-382-5p | Muscular dystrophy duchenne | MNDR-E-MI-47207 |
| MNDR | hsa-miR-382-5p | Head and neck cancer | MNDR-E-MI-47208 |
| MNDR | hsa-miR-382-5p | Huntington disease | MNDR-E-MI-47209 |
| MNDR | hsa-miR-382-5p | Chorea | MNDR-E-MI-47210 |
| MNDR | hsa-miR-382-5p | Lung cancer | MNDR-E-MI-47211 |
| MNDR | hsa-miR-382-5p | Fragile x syndrome | MNDR-E-MI-47212 |
| MNDR | hsa-miR-382-5p | Parkinson disease | MNDR-E-MI-47213 |
| MNDR | hsa-miR-382-5p | Niemann-pick disease | MNDR-E-MI-47214 |
| MNDR | hsa-miR-382-5p | Breast cancer | MNDR-E-MI-47215 |
| MNDR | hsa-miR-382-5p | Squamous cell carcinoma | MNDR-E-MI-47216 |
| MNDR | hsa-miR-382-5p | Thyroid cancer | MNDR-E-MI-47217 |
| MNDR | hsa-miR-382-5p | Pituitary neoplasms | MNDR-E-MI-47218 |
| MNDR | hsa-miR-382-5p | Pancreatic cancer | MNDR-E-MI-47219 |
| MNDR | hsa-miR-382-5p | Melanoma | MNDR-E-MI-47220 |
| MNDR | hsa-miR-382-5p | Nephroblastoma | MNDR-E-MI-47221 |
| MNDR | hsa-miR-382-5p | Ischemic attack transient | MNDR-E-MI-47222 |
| MNDR | hsa-miR-382-5p | Colon adenocarcinoma | MNDR-E-MI-47223 |
| MNDR | hsa-miR-382-5p | Familial ovarian cancer | MNDR-E-MI-47224 |
| MNDR | hsa-miR-382-5p | Carcinoma ductal breast | MNDR-E-MI-47225 |
| MNDR | hsa-miR-382-5p | Glioblastoma | MNDR-E-MI-47226 |
| MNDR | hsa-miR-382-5p | Glioma | MNDR-E-MI-47227 |
| MNDR | hsa-miR-382-5p | Nemaline myopathy | MNDR-E-MI-47228 |
| MNDR | hsa-miR-382-5p | Chordoma | MNDR-E-MI-47229 |
| MNDR | hsa-miR-382-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-47230 |
| MNDR | hsa-miR-382-5p | Osteosarcoma | MNDR-E-MI-47231 |
| MNDR | hsa-miR-382-5p | Meningioma | MNDR-E-MI-47232 |
| MNDR | hsa-miR-382-5p | Uterine cancer | MNDR-E-MI-47233 |
| MNDR | hsa-miR-382-5p | Gastric adenocarcinoma | MNDR-E-MI-47234 |
| MNDR | hsa-miR-382-5p | Bone-invasive pituitary adenoma | MNDR-E-MI-47235 |
| MNDR | hsa-miR-382-5p | Lung squamous cell carcinoma | MNDR-E-MI-47236 |
| MNDR | hsa-miR-382-5p | Lung adenocarcinoma | MNDR-E-MI-47237 |
| MNDR | hsa-miR-382-5p | Adrenocortical carcinoma | MNDR-E-MI-47238 |
| MNDR | hsa-miR-382-5p | Thyroid carcinoma | MNDR-E-MI-47239 |
| MNDR | hsa-miR-382-5p | Ovarian carcinoma | MNDR-E-MI-47240 |
| MNDR | hsa-miR-382-5p | Bladder urothelial carcinoma | MNDR-E-MI-47241 |
| MNDR | hsa-miR-382-5p | Pancreatic adenocarcinoma | MNDR-E-MI-47242 |
| MNDR | hsa-miR-382-5p | Carcinoma renal cell | MNDR-E-MI-47243 |
| MNDR | hsa-miR-382-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-47244 |
| MNDR | hsa-miR-382-5p | Clear cell renal cell carcinoma | MNDR-E-MI-47245 |
| MNDR | hsa-miR-382-5p | Adenocarcinoma of esophagus | MNDR-E-MI-47246 |
| MNDR | hsa-miR-382-5p | Esophageal cancer | MNDR-E-MI-47247 |
| MNDR | hsa-miR-382-5p | Prolactinoma | MNDR-E-MI-47248 |
| MNDR | hsa-miR-382-5p | Synovial sarcoma | MNDR-E-MI-47249 |
| MNDR | hsa-miR-382-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-47250 |
| MNDR | hsa-miR-382-5p | Breast invasive carcinoma | MNDR-E-MI-47251 |
| MNDR | hsa-miR-382-5p | Familiar ovarian carcinoma | MNDR-E-MI-47252 |
| MNDR | hsa-miR-382-5p | Retinoblastoma | MNDR-E-MI-47253 |
| MNDR | hsa-miR-382-5p | Skin cutaneous melanoma | MNDR-E-MI-47254 |
| MNDR | hsa-miR-382-5p | Skin melanoma | MNDR-E-MI-47255 |
| MNDR | hsa-miR-382-5p | Colorectal cancer | MNDR-E-MI-47256 |
| MNDR | hsa-miR-382-5p | Nasopharynx carcinoma | MNDR-E-MI-47257 |
| MNDR | hsa-miR-382-5p | Nasopharyngeal cancer | MNDR-E-MI-47258 |
| MNDR | hsa-miR-382-5p | Polymyositis | MNDR-E-MI-47259 |
| MNDR | hsa-miR-382-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-47260 |
| MNDR | hsa-miR-382-5p | Stroke lacunar | MNDR-E-MI-47261 |
| MNDR | hsa-miR-382-5p | Breast cancer her3+ negative | MNDR-E-MI-47262 |
| MNDR | hsa-miR-382-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-47263 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ATXN1 | Homo sapiens | RR00165932 |
TOP